Inbeeo’s Post

🚀 Exciting News and Throwback! 🚀 😊 In February 2024, VALAB, a leading player in France for the lab autoverification software, has been selected to participate in an acceleration program @FrenchHealthcare Booster Germany of Business France! ⭐ This incredible opportunity will allow us to immerse ourselves in one of Europe's most dynamic ecosystems, tapping into the vibrant innovation scene and leveraging the expertise of industry leaders and mentors. 🔎At VALAB, we're committed to driving meaningful change in the lab daily routine, and this program aligns perfectly with our vision. We're eager to collaborate with fellow innovators, explore new partnerships, and accelerate the development of groundbreaking solutions that 𝑤𝑖𝑙𝑙 𝑒𝑛ℎ𝑎𝑛𝑐𝑒 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑜𝑠𝑡-𝑎𝑛𝑎𝑙𝑦𝑡𝑖𝑐𝑎𝑙 𝑝ℎ𝑎𝑠𝑒 𝑜𝑓 𝑚𝑒𝑑𝑖𝑐𝑎𝑙 𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑜𝑟𝑖𝑒𝑠. 🤝 Great meet up and inspiring discussions with: Guenther Illert (Healthcare Shapers), David Sainati, Cécilia Mesa, Daniel Schaffer (Akkreditierte Labore in der Medizin e.V (ALM)), Dr. Michael MÜLLER (MVZ Labor 28 GmbH), Daniela Kahlert (Roche), Jens Riedel (MELOS - Medizinische Labor-Organisations-Systeme GmbH) 🙏 A huge shoutout to Constant CHAUDIER whose hard work and dedication have made this possible. Together, we're poised to make a lasting impact on the healthcare landscape. Stay tuned for updates as we embark on this exciting journey! #HealthcareInnovation #AccelerationProgram #Germany #ExpertSystem #InnovateWithPurpose 🚀🏥💡

Life Sciences - In Focus: Navigating the Regulatory Landscape – Latin America Edition https://lnkd.in/eK-F45rM Join us for this engaging panel discussion featuring esteemed guest speaker Sara Tylosky, MBA, CEO of Farmacon Global in discussion with Maria Mateos, Vistatec Life Sciences. June 27, 4 pm (GMT+1) | 5 pm (CET) | 8 am (PDT) This event will offer an in-depth look at the regulatory requirements across key Latin American countries, including crucial timelines and strategies to expedite approvals while avoiding common pitfalls. Discover the latest regulatory updates and trends as we explore their clinical research and development implications. Through case studies and real-world examples, learn from success stories and lessons gained from navigating the complex regulatory environment in Latin America. #LifeSciences #Vistatec

We are thrilled to invite you to "Life Sciences - In Focus: Navigating the Regulatory Landscape – Latin America Edition," featuring our esteemed CEO, Sara Tylosky, and Maria Mateos from Vistatec Life Sciences on June 27 at 4 pm GMT+1 / 5 pm CT / 8 am PT. Join us for an in-depth exploration of the regulatory requirements across key Latin American countries. We'll cover crucial timelines, strategies to expedite approvals, and ways to avoid common pitfalls. Discover the latest regulatory updates and trends and learn from real-world case studies and success stories. Whether you're currently working in Latin America or considering expanding your clinical research efforts there, this discussion is a must-attend! 🔗 Register Here: https://lnkd.in/eK-F45rM Don't miss this opportunity to gain valuable insights and connect with industry leaders. We look forward to seeing you there! #LifeSciences #ClinicalResearch #LatinAmerica #RegulatoryAffairs #Pharma #Biotech

How can cell therapy be made more efficient, cheaper and accessible? The trend towards Allogeneic treatment versus autologous is essential. Daring moves towards using multiple types of cells may open new horizons for a better cell therapy, a multicell therapy. Understanding the natural, physiological mechanisms of immunity and regeneration can help us too. Prevention based on rejuvenation using for example stem cells, lowering inflammation, may help avoiding cancer in the first place (Panel discussion themes and conclusions).

The morning after the night before. No, not that one. But the #BIOEurope drinks reception in Stockholm's Nacka Strand Bilfabriken. Thanks again to the excellent EBD Group for hosting another great event. Essential to connect with colleagues and industry partners, and also stay abreast of the latest biopharma thinking in the content sessions. I'm grateful to be able to share the perspectives from Citeline and Evaluate Ltd as part of Monday's industry trends session alongside Isma Hachi, PhD from IQVIA. The ecosystem is navigating funding and productivity challenges to continue to progress a healthy pipeline, although this cannot be taken for granted. Partnerships and deal-making is fundamental to this, but comments from the audience suggest that greater investment and autonomy for the biotech innovators would be welcome. Meanwhile, pharma companies backed by extensive scouting networks and large revenue streams continue to cherry pick treatments with the highest potential. Looking ahead, I'll be discussing some of the major conference themes in a webinar next Thursday (November 14) alongside the in-demand Melanie Senior, who moderated a handful of her own sessions at BIO-Europe. Please do join us - registration is free and available here: https://lnkd.in/e5K5FgqX

At BioStratiq, we consistently monitor and analyze transaction volumes in the life sciences sector. As Q3 2024 brings encouraging developments in Sweden’s healthcare and medical technology sectors, notable strategic deals in biotech and regional healthcare services are driving growth. Despite challenges like valuation gaps and high interest rates, investor appetite remains strong. With the BIO-Europe life science dealmaking conference taking place in Stockholm from November 4-6, the timing is perfect for life sciences M&A to gain further momentum. We’re hopeful this event will positively impact Swedish transaction activities as interest rate cuts are expected to stimulate even more deal-making in Q4. At BioStratiq, we are excited about these opportunities and remain committed to supporting our clients through tailored transaction advisory, valuations, and deal analysis. #Pharma #Biotech #Medtech #LifeSciences #Valuation #Licensing #BusinessDevelopment #BIOEurope

Are you attending this year's #BayOConnect event? Don't miss the chance to meet our experts Wafa and Angela, and discuss how we can support you in overcoming regulatory challenges and achieving your goals. #BayOConnect #biotech #regulatoryaffairs #pharmaregulatory #healthcare #medicine

Joining the Pharmaron team has been an incredible journey. Reflecting on my time here, I'm reminded of the profound symbolism embedded in the name "Pharmaron" itself. In Chinese, Pharmaron (康龙化成) embodies key values and principles that resonate deeply with our mission and vision. Let's delve into its meaning: Health (康): At Pharmaron, our foremost commitment is to improve global health outcomes. Every project, every innovation, and every endeavour is driven by the desire to enhance the well-being of individuals worldwide. Dragon (龙): The dragon is not just a mythical creature; it's a symbol of power, strength, and vitality in Chinese culture. It represents the vigour and dynamism that characterizes Pharmaron's approach to business—a relentless pursuit of excellence and success. Transformation/Chemistry (化): Transformation lies at the heart of what we do. Through groundbreaking research, innovative solutions, and strategic partnerships, we continuously strive to transform the landscape of drug discovery and development. Our expertise in chemistry serves as the foundation for these transformative endeavours, driving progress and innovation in the pharmaceutical industry. Success (成): Success is not merely an outcome; it's a journey marked by integrity, ethics, and dedication. At Pharmaron, we define success not only by achieving our goals but also by upholding the highest standards of ethical conduct, fostering a culture of trust and collaboration, and making a positive impact on society. As I reflect on the significance of Pharmaron's name, I'm reminded of the profound responsibility and privilege we have as stewards of health, innovation, and progress. Together, let's continue to embrace these values, drive positive change, and shape a brighter future for healthcare. And speaking of Pharmaron, meet our little mascot Kangzai; The Ying Dragon! 🐲 Isn't he adorable? He symbolizes the spirit of resilience, determination, and endless possibilities that inspire us at Pharmaron every day. #Pharmaron #Healthcare #Innovation #DrugDiscovery #TransformativeChemistry #Success #TeamWork

Go to Basel once, get on stage twice. We're thrilled to announce that TrialHub has been selected to participate in two prestigious events in Basel, showcasing our cutting-edge solutions in clinical and commercial aspects of the pharma and life sciences industries.   🔍 First Stop: #GenAI4Pharma at the Novartis Pavilion We will dive into the world of #GenerativeAI and its transformative potential across the biopharma lifecycle. From R&D to Clinical and beyond, it will be a day filled with exclusive insights and inspiring innovations. TrialHub will be presenting together with other top changemakers, like Accenture, Salesforce, AlphaMol Science Ltd, Ancora.ai, efficraft,  InSilicoTrials , Koios Care, and ReachRx. 🚀 Next Adventure: BOOM Summit Another round of innovation, discussions, and networking opportunities. TrialHub is amongst the top innovating companies worldwide, join us there and hear more about how we help not only Pharma companies, but most importantly - patients. Join TrialHub and our CEO, Maya Zlatanova, at these events. Don’t miss this chance to explore how we're quantifying patient burden and shaping the future of healthcare. #TrialHub #PharmaInnovation #LifeSciences #BaselEvents #ClinicalTriasl #innovation #clinicalresearch #FutureOfHealthcare #healthtech

🌍 Last week, Race in STEM's founder, Steven Fuller, was in Zug for a networking event where he connected with fellow leaders and advocates for diversity and inclusion in STEM. This event highlighted the importance of fostering an inclusive environment for underrepresented groups and sparked some great discussions. Explore some of the highlights below 👇 #RaceInSTEM #DiversityInSTEM #Leadership #InclusiveWorkplace #STEMAdvocacy